Atara Biotherapeutics Inc (ATRA) — Cash Flow-to-Debt Ratio
Atara Biotherapeutics Inc (ATRA) has a Cash Flow-to-Debt Ratio of -0.15x as of September 2025, meaning its operating cash flow of $-9.79 Million could theoretically repay 0% of its total liabilities ($66.80 Million) in one year. See cash generation quality of Atara Biotherapeutics Inc to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Atara Biotherapeutics Inc Cash Flow-to-Debt Ratio (2012–2024)
Historical debt coverage capacity for Atara Biotherapeutics Inc across 13 annual periods. Also explore ATRA net assets growth trend to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Atara Biotherapeutics Inc (2012–2024)
Year-by-year debt coverage analysis for Atara Biotherapeutics Inc. For market capitalisation and broader financial context, see ATRA company net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.33x | $-68.72 Million | $206.38 Million | ▲ +54.3% |
| 2023 | -0.73x | $-192.98 Million | $264.74 Million | ▲ +32.7% |
| 2022 | -1.08x | $-270.43 Million | $249.78 Million | ▲ +7.4% |
| 2021 | -1.17x | $-220.52 Million | $188.51 Million | ▲ +18.6% |
| 2020 | -1.44x | $-180.76 Million | $125.78 Million | ▲ +68.2% |
| 2019 | -4.52x | $-235.63 Million | $52.16 Million | ▼ -33.1% |
| 2018 | -3.39x | $-179.77 Million | $52.98 Million | ▼ -54.8% |
| 2017 | -2.19x | $-87.50 Million | $39.91 Million | ▲ +62.8% |
| 2016 | -5.90x | $-60.02 Million | $10.18 Million | ▼ -56.7% |
| 2015 | -3.76x | $-37.16 Million | $9.88 Million | ▲ +33.5% |
| 2014 | -5.66x | $-16.63 Million | $2.94 Million | ▼ -5857.7% |
| 2013 | -0.09x | $-5.97 Million | $62.84 Million | ▲ +69.2% |
| 2012 | -0.31x | $-2.48 Million | $8.02 Million | — |